PAEAN's proprietary platform technology facilitates the engineering of modified mitochondria capable of delivering therapeutic agents to designated cellular targets. This innovative technology integrates mitochondria with single-chain variable fragments of antibodies specifically designed to interact with target cells (called as CAR-Mito). Additionally, there is the capability to conjugate anti-cancer agents or chemical payloads to these modified mitochondria, thereby enhancing their efficacy in selectively targeting and killing cancer cells (called as AMDC).
The conjugation of antibodies to mitochondria ensures specificity in targeting, allowing precise therapeutic interventions tailored to specific cell types or pathological states. By harnessing the intrinsic capabilities of mitochondria and the specificity of antibody-mediated targeting, CAR-Mito holds the potential to address a wide range of mitochondrial disorders.
This novel therapeutic approach involves the conjugation of specific antibodies that target cancer cells to mitochondria, which serve as precision delivery vehicles for anti-cancer drugs. AMDC potentially enhances selectivity and efficacy, minimizing off-target effects while improving therapeutic outcomes.
Headquarter : #108SB, DaeduckBiz Center
17 Techno 4-ro, Yuseong-gu, Daejeon 34013, Korea
Mail : info@paeanbio.com
Phone : 042-334-7378 | Fax : 042-334-7096
Copyrights © 2025 All Rights Reserved by PAEAN BIOTECHNOLOGY